Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.  Dr. Low has devoted over 45 years to developing novel drugs for treatment of human diseases and characterizing the structure, function and pathologies of the human red blood cell. He has published more than 500 scientific articles and has over 100 US patents/patents pending. Eight drugs stemming from his research are currently undergoing human clinical trials in the areas of: i) tumor-targeted drugs for the imaging and therapy of cancer, ii) a new therapy for malaria, iii) a novel treatment for sickle cell disease, iv) tumor-targeted fluorescent dyes for image-guided surgery of cancer, and v) novel imaging and therapeutic agents for inflammatory and autoimmune diseases. From his research he has founded or cofounded seven companies.  His initial company, Endocyte, sold to Novartis for $2.1B in 2018. Dr. Low has received an NIH MERIT Award, the American Chemical Society’s Award for Cancer Research (Sosnovsky Award), the American Association for Cancer Research’s (AACR) Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from UCSD (1975).